Gpnmb/osteoactivin, an attractive target in cancer immunotherapy

Neoplasma

Volumn 59, Issue 1, 2012, Pages 1-5

  Zhou, L T ^a   Liu, F Y ^a   Li, Y ^a   Peng, Y M ^a   Liu, Y H ^a   Li, J ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Cancer immunotherapy; Glycoprotein non metastatic melanoma protein B; Osteoactivin

Indexed keywords

F6V; GELATINASE B; GLEMBATUMUMAB; GLEMBATUMUMAB VEDOTIN; GLYCOPROTEIN; MELANIN; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOACTIVIN; PE38; STROMELYSIN; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; GPNMB PROTEIN, HUMAN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; OLIGOPEPTIDE; TUMOR PROTEIN;

BREAST CANCER; CANCER IMMUNOTHERAPY; CLINICAL TRIAL (TOPIC); DRUG TARGETING; GLIOMA; HUMAN; LIVER CELL CARCINOMA; MELANOMA; NONHUMAN; OSTEOARTHRITIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; RASH; REVIEW; STRUCTURAL HOMOLOGY; ANIMAL; BREAST TUMOR; CANCER INVASION; CARCINOMA; CELL MOTION; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; DRUG ERUPTION; DRUG SCREENING; FEMALE; IMMUNOLOGY; MALE; MOLECULARLY TARGETED THERAPY; NEOPLASM; OSTEOBLAST; OSTEOLYSIS; PHYSIOLOGY; RAT; SKIN TUMOR;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BONE RESORPTION; BREAST NEOPLASMS; CARCINOMA; CELL MOVEMENT; CLINICAL TRIALS AS TOPIC; DRUG ERUPTIONS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; IMMUNOCONJUGATES; MALE; MELANOMA; MEMBRANE GLYCOPROTEINS; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASMS; OLIGOPEPTIDES; OSTEOBLASTS; RATS; SKIN NEOPLASMS;

EID: 84863745351     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2012_001     Document Type: Review

References (40)

1. TSE KF, JEFFERS M, POLLACK VA, MCCABE DA, SHADISH ML et al. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res 2006; 12: 1373-1382. http://dx.doi. org/10.1158/1078-0432.CCR-05-2018
2. RIPOLL VM, IRVINE KM, RAVASI T, SWEET MJ, HUME DA Gpnmb is induced in macrophages by IFN-gamma and lipopolysaccharide and acts as a feedback regulator of proinflammatory responses. J Immunol 2007; 178: 6557-6566.
3. TOMIHARI M, HWANG SH, CHUNG JS, CRUZ PD JR, ARIIZUMI K Gpnmb is a melanosome-associated glycoprotein that contributes to melanocyte/keratinocyte adhesion in a RGD-dependent fashion. Exp Dermatol 2009; 18: 586-595. http://dx.doi.org/10.1111/j.1600-0625.2008.00830.x
4. RICH JN, SHI Q, HJELMELAND M, CUMMINGS TJ, KUAN CT et al. Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. J Biol Chem 2003; 278: 15951-15957. http://dx.doi.org/10.1074/jbc.M211498200
5. KUAN CT, WAKIYA K, DOWELL JM, HERNDON JE 2ND, REARDON DA et al. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res 2006; 12: 1970-1982. http://dx.doi.org/10.1158/1078-0432.CCR-05-2797
6. ROSE AA, PEPIN F, RUSSO C, ABOU KHALIL JE, HALLETT M et al. Osteoactivin promotes breast cancer metastasis to bone. Mol Cancer Res 2007; 5: 1001-1014. http://dx.doi. org/10.1158/1541-7786.MCR-07-0119
7. ONAGA M, IDO A, HASUIKE S, UTO H, MORIUCHI A et al. Osteoactivin expressed during cirrhosis development in rats fed a choline-deficient, L-amino acid-defined diet, accelerates motility of hepatoma cells. J Hepatol 2003; 39: 779-785. http://dx.doi.org/10.1016/S0168-8278(03)00361-1
8. SAFADI FF, XU J, SMOCK SL, RICO MC, OWEN TA et al. Cloning and characterization of osteoactivin, a novel cDNA expressed in osteoblasts. J Cell Biochem 2001; 84: 12-26.
9. SHIKANO S, BONKOBARA M, ZUKAS PK, ARIIZUMI K Molecular cloning of a dendritic cell-associated transmembrane protein, DC-HIL, that promotes RGD-dependent adhesion of endothelial cells through recognition of heparan sulfate proteoglycans. J Biol Chem 2001; 276: 8125-8134. http://dx.doi.org/10.1074/jbc.M008539200
10. METZ RL, PATEL PS, HAMEED M, BRYAN M, RAMESHWAR P Role of human HGFIN/nmb in breast cancer. Breast Cancer Res 2007; 9: R58. http://dx.doi.org/10.1186/bcr1764
11. SELIM AA, ABDELMAGID SM, KANAAN RA, SMOCK SL, OWEN TA et al. Anti-osteoactivin antibody inhibits osteoblast differentiation and function in vitro. Crit Rev Eukaryot Gene Expr 2003; 13: 265-275.
12. ABDELMAGID SM, BARBE MF, RICO MC, SALIHOGLU S, ARANGO-HISIJARA I et al. Osteoactivin, an anabolic factor that regulates osteoblast differentiation and function. Exp Cell Res 2008; 314: 2334-2351. http://dx.doi.org/10.1016/j.yexcr.2008.02.006
13. RIPOLL VM, MEADOWS NA, RAGGATT LJ, CHANG MK, PETTIT AR et al. Microphthalmia transcription factor regulates the expression of the novel osteoclast factor GPNMB. Gene 2008; 413: 32-41. http://dx.doi.org/10.1016/j.gene.2008.01.014
14. SHENG MH, WERGEDAL JE, MOHAN S, LAU KH Osteoactivin is a novel osteoclastic protein and plays a key role in osteoclast differentiation and activity. FEBS Lett 2008; 582: 1451-1458. http://dx.doi.org/10.1016/j.febslet.2008.03.030
15. AHN JH, LEE Y, JEON C, LEE SJ, LEE BH et al. Identification of the genes differentially expressed in human dendritic cell subsets by cDNA subtraction and microarray analysis. Blood 2002; 100: 1742-1754.
16. HOASHI T, SATO S, YAMAGUCHI Y, PASSERON T, TAMAKI K et al. Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome-specific and proteolytically released protein. Faseb J 2010; 24: 1616-1629. http://dx.doi.org/10.1096/fj.09-151019
17. OWEN TA, SMOCK SL, PRAKASH S, PINDER L, BREES D et al. Identification and characterization of the genes encoding human and mouse osteoactivin. Crit Rev Eukaryot Gene Expr 2003; 13: 205-220.
18. ANDERSON MG, SMITH RS, HAWES NL, ZABALETA A, CHANG B et al. Mutations in genes encoding melanosomal proteins cause pigmentary glaucoma in DBA/2J mice. Nat Genet 2002; 30: 81-85. http://dx.doi.org/10.1038/ng794
19. LI B, CASTANO AP, HUDSON TE, NOWLIN BT, LIN SL et al. The melanoma-associated transmembrane glycoprotein Gpnmb controls trafficking of cellular debris for degradation and is essential for tissue repair. Faseb J 2010; 24: 4767-4781. http://dx.doi.org/10.1096/fj.10-154757
20. PAHL MV, VAZIRI ND, YUAN J, ADLER SG Upregulation of monocyte/macrophage HGFIN (Gpnmb/Osteoactivin) expression in end-stage renal disease. Clin J Am Soc Nephrol 2010; 5: 56-61. http://dx.doi.org/10.2215/CJN.03390509
21. NAKAMURA A, ISHII A, OHATA C, KOMURASAKI T Early induction of osteoactivin expression in rat renal tubular epithelial cells after unilateral ureteral obstruction. Exp Toxicol Pathol 2007; 59: 53-59. http://dx.doi.org/10.1016/j.etp.2007.03.005
22. KARLSSON C, DEHNE T, LINDAHL A, BRITTBERG M, PRUSS A et al. Genome-wide expression profiling reveals new candidate genes associated with osteoarthritis. Osteoarthritis Cartilage 2010; 18: 581-592. http://dx.doi. org/10.1016/j.joca.2009.12.002
23. WILLIAMS MD, ESMAELI B, SOHEILI A, SIMANTOV R, GOMBOS DS et al. GPNMB expression in uveal melanoma: a potential for targeted therapy. Melanoma Res 2010; 20: 184-190.
24. ROSE AA, GROSSET AA, DONG Z, RUSSO C, MACDONALD PA et al. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Clin Cancer Res 2010; 16: 2147-2156. http://dx.doi.org/10.1158/1078-0432.CCR-09-1611
25. WETERMAN MA, AJUBI N, VAN DINTER IM, DEGEN WG, VAN MUIJEN GN et al. nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts. Int J Cancer 1995; 60: 73-81. http://dx.doi.org/10.1002/ijc.2910600111
26. GHILARDI C, CHIORINO G, DOSSI R, NAGY Z, GIAVAZZI R et al. Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium. BMC Genomics 2008; 9: 201. http://dx.doi.org/10.1186/1471-2164-9-201
27. OGAWA T, NIKAWA T, FUROCHI H, KOSYOJI M, HIRASAKA K et al. Osteoactivin upregulates expression of MMP-3 and MMP-9 in fibroblasts infiltrated into denervated skeletal muscle in mice. Am J Physiol Cell Physiol 2005; 289: C697-707. http://dx.doi.org/10.1152/ajpcell.00565.2004
28. CHUNG JS, DOUGHERTY I, CRUZ PD JR, ARIIZUMI K Syndecan-4 mediates the coinhibitory function of DC-HIL on T cell activation. J Immunol 2007; 179: 5778-5784.
29. CHUNG JS, SATO K, DOUGHERTY II, CRUZ PD JR, ARIIZUMI K DC-HIL is a negative regulator of T lymphocyte activation. Blood 2007; 109: 4320-4327. http://dx.doi. org/10.1182/blood-2006-11-053769
30. CHUNG JS, YUDATE T, TOMIHARI M, AKIYOSHI H, CRUZ PD JR et al. Binding of DC-HIL to dermatophytic fungi induces tyrosine phosphorylation and potentiates antigen presenting cell function. J Immunol 2009; 183: 5190-5198. http://dx.doi.org/10.4049/jimmunol.0901319
31. TOMIHARI M, CHUNG JS, AKIYOSHI H, CRUZ PD JR, ARIIZUMI K DC-HIL/glycoprotein Nmb promotes growth of melanoma in mice by inhibiting the activation of tumorreactive T cells. Cancer Res 2010; 70: 5778-5787. http://dx.doi. org/10.1158/0008-5472.CAN-09-2538
32. CHUNG JS, BONKOBARA M, TOMIHARI M, CRUZ PD JR, ARIIZUMI K The DC-HIL/syndecan-4 pathway inhibits human allogeneic T-cell responses. Eur J Immunol 2009; 39: 965-974. http://dx.doi.org/10.1002/eji.200838990
33. ROSE AA, ANNIS MG, DONG Z, PEPIN F, HALLETT M et al. ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties. PLoS One 2010; 5: e12093. http://dx.doi.org/10.1371/journal. pone.0012093
34. HARALANOVA-ILIEVA B, RAMADORI G, ARMBRUST T Expression of osteoactivin in rat and human liver and isolated rat liver cells. J Hepatol 2005; 42: 565-572. http://dx.doi. org/10.1016/j.jhep.2004.12.021
35. CARTER PJ, SENTER PD Antibody-drug conjugates for cancer therapy. Cancer J 2008; 14: 154-169. http://dx.doi. org/10.1097/PPO.0b013e318172d704
36. POLLACK VA, ALVAREZ E, TSE KF, TORGOV MY, XIE S et al. Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB. Cancer Chemother Pharmacol 2007; 60: 423-435. http://dx.doi.org/10.1007/s00280-007-0490-z
37. QIAN X, MILLS E, TORGOV M, LAROCHELLE WJ, JEFFERS M Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vc-MMAE antibody-drug conjugate. Mol Oncol 2008; 2: 81-93. http://dx.doi.org/10.1016/j.molonc.2008.02.002
38. KUAN CT, WAKIYA K, KEIR ST, LI J, HERNDON JE 2ND et al. Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas. Int J Cancer 2011; 129: 111-121. http://dx.doi.org/10.1002/ijc.25645
39. ABDELMAGID SM, BARBE MF, ARANGO-HISIJARA I, OWEN TA, POPOFF SN et al. Osteoactivin acts as downstream mediator of BMP-2 effects on osteoblast function. J Cell Physiol 2007; 210: 26-37. http://dx.doi.org/10.1002/jcp.20841
40. LOFTUS SK, ANTONELLIS A, MATERA I, RENAUD G, BAXTER LL et al. Gpnmb is a melanoblast-expressed, MITFdependent gene. Pigment Cell Melanoma Res 2009; 22: 99-110. http://dx.doi.org/10.1111/j.1755-148X.2008.00518.x